TOP > 外国特許検索 > TUMOR CELL MALIGNANT TRANSFORMATION SUPPRESSOR AND ANTI-TUMOR AGENT

TUMOR CELL MALIGNANT TRANSFORMATION SUPPRESSOR AND ANTI-TUMOR AGENT

外国特許コード F170008935
整理番号 (AF42P001)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP062757
国際公開番号 WO 2016178374
国際出願日 平成28年4月22日(2016.4.22)
国際公開日 平成28年11月10日(2016.11.10)
優先権データ
  • 特願2015-093980 (2015.5.1) JP
発明の名称 (英語) TUMOR CELL MALIGNANT TRANSFORMATION SUPPRESSOR AND ANTI-TUMOR AGENT
発明の概要(英語) The present invention provides an anti-tumor agent and a suppressor for suppressing malignant transformation of tumor cells through means such as acquisition of metastasis capability and acquisition of apoptosis resistance. The present invention pertains to: a tumor cell malignant transformation suppressor that suppresses or inhibits acquisition of metastasis capability or acquisition of apoptosis resistance by tumor cells and of which the active ingredient is a substance that suppresses or inhibits the function of the Zic5 gene; a method for suppressing malignant transformation of tumor cells in an animal other than human, wherein acquisition of metastasis capability or acquisition of apoptosis resistance by tumor cells is suppressed or inhibited by suppressing or inhibiting the function of the Zic5 gene; an anti-tumor agent that is used for treating prostate cancer and of which the active ingredient is a substance that suppresses or inhibits the function of the Zic5 gene; and a tumor cell malignancy marker which is the expression level of the Zic5 gene.
特許請求の範囲(英語) [claim1]
1. The substance which you control or obstruct function of the Zic5 gene, or is designated as the active ingredient, transfer efficiency acquisition or [apotoshisu] resistant acquisition of the tumor cell controls or is obstructed, or, the malignant conversion inhibiter of the tumor cell.
[claim2]
2. The substance which you control or obstruct function of the aforementioned Zic5 gene, or, is siRNA which designates the Zic5 gene as the target, in claim 1 the malignant conversion inhibiter of the tumor cell of statement.
[claim3]
3. The substance which you control or obstruct function of the aforementioned Zic5 gene, or, is the substance, the substance which obstructs nuclear localized of the Zic5 protein or disassembles the Zic5 protein the substance which obstruct the interaction of the Zic5 protein and promoter arrangement of the gene which [E]-kadoherin the cord/code is done, in claim 1 the malignant conversion inhibiter of the tumor cell of statement.
[claim4]
4. The aforementioned tumor cell, is the melanoma cell or the prostate cancer cell, either of the claim 1-3 in one section the malignant conversion inhibiter of the tumor cell of statement.
[claim5]
5. The aforementioned tumor cell, has BRAF inhibiter tolerance, either of the claim 1-4 in one section the malignant conversion inhibiter of the tumor cell of statement.
[claim6]
6. Being the method of controlling the malignancy conversion of the tumor cell of the animal other than the person,
You control or obstruct the transfer efficiency acquisition or [apotoshisu] resistant acquisition of the tumor cell by controlling or obstructs function of the Zic5 gene, or, malignant conversion control method of the tumor cell.
[claim7]
7. It does control or obstruction of function of the Zic5 gene, with RNA interference, by obstructing the revelation of the Zic5 gene, in claim 6 malignant conversion control method of the tumor cell of statement.
[claim8]
8. It designates the substance which you control or obstruct function of the Zic5 gene, or as the active ingredient, is used for the remedy of the melanoma, the anti- tumor medicine.
[claim9]
9. It is used for the remedy of the melanoma which possesses BRAF inhibiter tolerance or the melanoma which does not have the remedy aptitude to the BRAF inhibiter, in claim 8 the anti- tumor medicine of statement.
[claim10]
10. It designates the substance which you control or obstruct function of the Zic5 gene, or as the active ingredient, is used for the remedy of the prostate cancer, the anti- tumor medicine.
[claim11]
11. The substance which you control or obstruct function of the aforementioned Zic5 gene, or, is siRNA which designates the Zic5 gene as the target, either of the claim 8-10 in one section the anti- tumor medicine of statement.
[claim12]
12. It consists of the revelation quantity of the Zic5 gene, the degree of malignant marker of the tumor cell.
[claim13]
13. The revelation quantity of the Zic5 gene of the suffering inspection tumor cell is designated as the marker,
You appraise, that the extent where the revelation quantity of the Zic5 gene of the suffering inspection tumor cell is many, degree of malignancy is high degree of malignant evaluation method of the tumor cell.
[claim14]
14. The aforementioned suffering inspection tumor cell is the field occurrence tumor cell, you appraise, that the revelation quantity of the Zic5 gene of the aforementioned suffering inspection tumor cell, when it is above specified threshold, the risk where the aforementioned suffering inspection tumor cell acquires transfer efficiency or [apotoshisu] resistance is high, in claim 13 degree of malignant evaluation method of the tumor cell of statement.
[claim15]
15. It consists of the revelation quantity of the Zic5 gene, detects the melanoma or prostate cancer, the tumor marker.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • FUKAMI KIYOKO
  • SATOW REIKO
国際特許分類(IPC)
指定国 (WO2016178374)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) CREST Creation of Innovative Technology for Medical Applications Based on the Global Analyses and Regulation of Disease-Related Metabolites AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close